
eMethods. Race/Ethnicity Classification

eTable. Sensitivity Analysis Removing Overdoses Potentially Related To Surgical Anesthesia

eFigure 1. Share of Extended-Release Oxycodone Dispensings by Generic and Brand (OxyContin) Non–Abuse-Deterrent Formulations and Abuse-Deterrent OxyContin From 2003 Through 2012

eFigure 2. Annual Mean Out-of-Pocket Cost (Copayment Plus Deductible) per Dispensing for OxyContin for Non–Abuse-Deterrent Formulation (2003-2009) and Abuse-Deterrent Formulation (2011-2012) With Mixed Data When the Abuse-Deterrent Formulation Was Introduced in 2010

This supplementary material has been provided by the authors to give readers additional information about their work.
eMethods. Race/Ethnicity Classification

We classified members as residing in white, black, or Hispanic neighborhoods based on living in neighborhoods with 75% or more persons of the given race/ethnicity; we assigned census blocks with 75% or more persons of both Hispanic ethnicity and black race to the Hispanic category. We classified members from census block groups that did not fall into one of the three race/ethnicity categories as living in mixed race/ethnicity neighborhoods. We used surname analysis to identify Hispanic and Asian individuals which superseded the neighborhood-based measure; we classified members as Hispanic if they lived in a predominantly Hispanic neighborhood or had a Hispanic surname.
<table>
<thead>
<tr>
<th>Scenario</th>
<th>Change in prescription opioid overdose rate at 2 years per 100 000 members per quarter</th>
<th>Absolute change (95% CI)</th>
<th>Relative change, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>All overdoses</td>
<td></td>
<td>-1.10 (-1.47 to -0.74)</td>
<td>-20.1%</td>
</tr>
<tr>
<td>Anesthesia-related overdoses removed</td>
<td></td>
<td>-1.13 (-1.49 to -0.76)</td>
<td>-21.1%</td>
</tr>
</tbody>
</table>
eFigure 1. Share of Extended-Release Oxycodone Dispensings by Generic and Brand (OxyContin) Non-Abuse-Deterrent Formulations and Abuse-Deterrent OxyContin From 2003 Through 2012.
**eFigure 2.** Annual Mean Out-of-Pocket Cost (Copayment Plus Deductible) per Dispensing for OxyContin for Non–Abuse-Deterrent Formulation (2003-2009) and Abuse-Deterrent Formulation (2011-2012) With Mixed Data When the Abuse-Deterrent Formulation Was Introduced in 2010